Digital ExclusiveOrthobiologics for the Management of Early Arthritis in the Middle-Aged AthleteRauck, Ryan C. MD*; Eliasberg, Claire D. MD†; Rodeo, Scott BS†; Rodeo, Scott A. MD† Author Information *Department of Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, OH †Hospital for Special Surgery, New York, NY Disclosure: S.A.R. Ortho RTI: stock or stock options and Teladoc: paid consultant. The remaining authors declare no conflict of interest. Reprints: Ryan C. Rauck, MD, 535 East 70th Street, New York, NY 10021. Sports Medicine and Arthroscopy Review: June 2022 - Volume 30 - Issue 2 - p e9-e16 doi: 10.1097/JSA.0000000000000337 Buy Metrics Abstract This article is dedicated to the use of orthobiologic therapies in the management of early osteoarthritis in middle-aged athletes. Understanding a patient’s presenting symptoms, physical examination, imaging results, and goals is of critical importance in applying orthobiologic therapies. The field of orthobiologics is expanding at a rapid pace, and the clinical studies examining the utility of each treatment lag behind the direct-to-consumer marketing that leads to these products being used. Here we provide a review of the available treatments, emerging treatments, and the current literature supporting or refuting their use. Currently studied orthobiologics include autologous and allogenic cell therapies, autologous blood products, hyaluronic acid, gene therapies, Wnt inhibitors, and a variety of systemic treatments. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.